AARTIDRUGS — Aarti Drugs Share Price
0.000.00%
Last trade - 00:00- IN₹32.02bn
- IN₹37.63bn
- IN₹25.29bn
- 86
- 28
- 33
- 48
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.51 | ||
| Price to Tang. Book | 2.51 | ||
| Price to Free Cashflow | 31.41 | ||
| Price to Sales | 1.37 | ||
| EV to EBITDA | 13.46 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 13.65% | ||
| Return on Equity | 12.27% | ||
| Operating Margin | 9.66% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 18,060.88 | 21,547.8 | 24,886.46 | 27,160.54 | 25,285.76 | 36,092 | n/a | 10.13% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +60.22 | +103.09 | -26.36 | -18.89 | +3.9 | +105.79 | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Aarti Drugs Limited is an India-based company, which is engaged in manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include iprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole, ofloxacin, and others. Its specialty chemicals includes benzene sulphonyl chloride, methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include alpha lipoic acid, itraconazole, ticagrelor, and sitagliptin. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited, and Pinnacle Chile SPA.
Directors
- Prakash Patil CHM (68)
- Chandrakant Gogri NEC (74)
- Rushikesh Deole CCO
- Harshit Savla MDR (52)
- Rashesh Gogri EDR (47)
- Uday Patil EDR (52)
- Harit Pragji Shah EDR (51)
- Rajendra Gogri NED (55)
- Ankit Paleja IND
- Priti Savla IND (44)
- Krishnacharya Akamanchi NID (62)
- Vilas Gaikar NID (54)
- Navin Shah NID (54)
- Bhavesh Vora NID (48)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- September 28th, 1984
- Public Since
- May 12th, 1993
- No. of Shareholders
- 161,066
- No. of Employees
- 1,064
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 91,270,000
- Address
- Mahendra Industrial Estate,, MUMBAI, 400022
- Web
- https://www.aartidrugs.co.in/
- Phone
- +91 2224019025
- Contact
- Rushikesh Deole
- Auditors
- Gokhale & Sathe
Upcoming Events for AARTIDRUGS
Q1 2026 Aarti Drugs Ltd Earnings Release
Q2 2026 Aarti Drugs Ltd Earnings Release
Similar to AARTIDRUGS
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
Ajanta Pharma
National Stock Exchange of India
FAQ
What is the Aarti Drugs share price?
As of Today at 19:00 UTC, shares in Aarti Drugs are trading at IN₹350.80. This share price information is delayed by 15 minutes.
How has the Aarti Drugs share price performed this year?
Shares in Aarti Drugs last closed at IN₹350.80 and the price had moved by -29.87% over the past 365 days. In terms of relative price strength the Aarti Drugs share price has underperformed the S&P BSE 100 Index by -33.93% over the past year.
What are the analyst and broker recommendations for Aarti Drugs?
The overall consensus recommendation for Aarti Drugs is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Aarti Drugs dividend yield?
The Aarti Drugs dividend yield is 0.29% based on the trailing twelve month period.
Does Aarti Drugs pay a dividend?
Last year, Aarti Drugs paid a total dividend of IN₹1.00, and it currently has a trailing dividend yield of 0.29%. We do not have any data on when Aarti Drugs is to next pay dividends.
When does Aarti Drugs next pay dividends?
We do not have data on when Aarti Drugs is to next pay dividends. The historic dividend yield on Aarti Drugs shares is currently 0.29%.
How do I buy Aarti Drugs shares?
To buy shares in Aarti Drugs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Aarti Drugs?
As of the previous close price of IN₹350.80, shares in Aarti Drugs had a market capitalisation of IN₹32.02bn.
Where are Aarti Drugs shares listed?
Here are the trading details for Aarti Drugs:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: AARTIDRUGS
What kind of share is Aarti Drugs?
Based on an overall assessment of its quality, value and momentum Aarti Drugs is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Aarti Drugs share price forecast for 2025?
The analyst consensus target price for shares in Aarti Drugs is IN₹615.00. That is 75.31% above the last closing price of IN₹350.80.
Analysts covering Aarti Drugs currently have a consensus Earnings Per Share (EPS) forecast of IN₹38.40 for the next financial year.
Find out moreWhat is the trend in the Aarti Drugs share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aarti Drugs. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -24.54%.
As of the last closing price of IN₹350.80, shares in Aarti Drugs were trading -23.15% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Aarti Drugs PE Ratio?
The Aarti Drugs PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹350.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Aarti Drugs?
Aarti Drugs' management team is headed by:
- Prakash Patil - CHM
- Chandrakant Gogri - NEC
- Rushikesh Deole - CCO
- Harshit Savla - MDR
- Rashesh Gogri - EDR
- Uday Patil - EDR
- Harit Pragji Shah - EDR
- Rajendra Gogri - NED
- Ankit Paleja - IND
- Priti Savla - IND
- Krishnacharya Akamanchi - NID
- Vilas Gaikar - NID
- Navin Shah - NID
- Bhavesh Vora - NID